NC-PERCONA
27.3.2024 14:01:35 CET | Business Wire | Press release
Percona, a leader in enterprise-grade, open source database software, support, and services, has entered 2024 fresh off a year marked by sustained customer growth, multiple prestigious award wins, and innovative product enhancements. The company's impressive 2023 has further solidified its standing as a go-to provider of open source database solutions and support services.
Having predicted the database market to clear $100 billion in 2023, Gartner forecasts the market to grow at a compound annual growth rate (CAGR) of 16.8% through 2027 and reach $203.6 billion. This underscores sustained demand for sophisticated database management expertise to ensure optimal performance, security, and reliability. Uniquely qualified to address these needs, Percona has capitalized on the expanding opportunity, realizing a 19% increase in Annual Recurring Revenue (ARR).
Customer-Led Growth
Fueled by ongoing innovation and an unwavering commitment to customer success, Percona has continued to broaden its customer base — with both new customer acquisitions and expanded relationships with existing customers contributing to its fully organic growth.
One notable example, EveryMatrix, a prominent iGaming software provider, has benefited from Percona's managed services expertise, optimizing their database management for MySQL, MariaDB, and PostgreSQL. This collaboration has resulted in enhanced database performance, resilience, and security, empowering EveryMatrix to focus on innovation and customer satisfaction within the highly competitive online gaming industry.
Similarly, PagerDuty relies on Percona's support for MySQL, ensuring reliable and high-performance database instances critical to PagerDuty's operations. Percona's proactive assistance, including end-of-life support for MySQL 5.7 and migration planning, underscores its commitment to delivering exceptional support and expertise to its clientele.
2023 also saw some of the world’s most recognizable brands signing on with Percona or expanding the scope of their engagement. Percona began supporting companies such as Netflix and the United States Geological Survey. The company expanded its scope further by partnering with Merchant Warrior, Otto Office, and Kontron, among others.
Awards and Recognition
Percona’s track record as a leader in the open source database community yielded several prestigious awards and acknowledgments in 2023.
Most recently, the company secured the title of "Best DevOps for DataOps/Database Solution" at the Devops Dozen awards, illustrating its commitment to delivering cutting-edge solutions tailored to modern DevOps practices. Additionally, Percona's innovative products have been featured among the trend-setting products in data and information management for 2024 by DBTA (Database Trends and Applications), further validating its position as an industry trailblazer.
Moreover, Percona thought leaders like CEO Ann Schlemmer and Technology Evangelist Dave Stokes have garnered attention in publications such as Forbes, Computer Weekly, InfoWorld, The New Stack, The Register, and more. In these thought pieces Percona’s leaders have spearheaded discussions on data and open source, shaping the discourse around emerging trends and best practices.
Innovations and Enhancements
Percona continued to push the boundaries of database innovation with the recent Beta release of Percona Everest, an open source cloud-native database platform. Percona Everest is the first open source solution that combines multi-cloud and multi-database capabilities in one platform. With an intuitive user interface (UI) and command-line interface (CLI), Percona Everest offers advanced database provisioning and management features at no cost while providing control over infrastructure expenses, eliminating vendor lock-in.
Percona Everest allows users to enjoy flexible features such as provisioning, scalability, performance optimization, and high availability with full automation. By integrating with Kubernetes Operators, Percona Everest empowers users to run databases anywhere, liberating them from the constraints of public cloud platforms.
In addition to the Beta release of Percona Everest, Percona introduced numerous enhancements and updates to its product lineup over the course of 2023, including:
- A complete post-EOL support program for MySQL 5.7, which allows participating customers to continue to operate on a fully supported Percona Server for MySQL 5.7 until upgrading to later major versions becomes more convenient. Within this program, Percona continues to release the CVE-patched versions of MySQL 5.7 to participating customers.
- Percona Monitoring and Management (PMM) introduced MongoDB backup monitoring capabilities, which provide users with a streamlined backup and restore process and improved inventory management.
Primed for Growth
Looking ahead, Percona is poised for continued expansion. The company remains steadfast in its mission to make enterprise databases run better through a unique blend of expertise and open source software.
"As we reflect on our recent achievements and the strides we've made in 2023, it's clear that all the attributes customers value in a vendor – dedication to innovation, customer-centric solutions, and fostering meaningful relationships – are moving Percona in the right direction," said Ann Schlemmer, CEO of Percona. "We are proud of each milestone we’ve reached and the incredible team that has gotten us here, and we look forward to continuing our commitment to driving progress."
Percona will reaffirm its leadership within the open source database community by participating in key industry events throughout 2024, including KubeCon North America and Open Source Summit North America. At these events, and many others, Percona will continue to expand its impact on the open source database community.
Learn more about how databases perform better with Percona.
About Percona:
Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available.
Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327240035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom